Johnson & Johnson
JNJFull coverage—Johnson & Johnson
JNJNew York Stock ExchangeFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Johnson & Johnson sells prescription drugs and medical devices, and its third quarter of fiscal 2026 showed new medicines such as TREMFYA, DARZALEX and CARVYKTI replacing the fast-shrinking STELARA: sales grew 5.9% to $25.4 billion and the company raised its full-year sales guidance again. Diluted EPS fell to $0.09 because of a $5.5 billion charge for a proposed ovarian talc settlement that still needs 95% of claimants to join, while the device business slowed for the third quarter running. The next test is 2027, when products with $4 billion to $4.5 billion of sales lose patent protection, by the CFO's count. Moatsight estimates revenue of about $105.3 billion and free cash flow of about $19.5 billion over the next four quarters.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers